PR
Public Relations
Home
PR
Media release
EGFR Lung Cancer Game Changer “Tagrisso”, In Development to Expand Indication to Early-Stage Patients
NOTICE
2023-07-25

EGFR Lung Cancer Game Changer "Tagrisso," In Development to Expand Indication to Early-Stage Patients

 

 

 

 

Source: “the Bell', the Capital Market Media

 

 

 

An article was published on the same topic as above.

Especially in the “Leclaza Chases Tagrisso... Korean Companies Targeting Diverse Genetic Mutations" section, Therapex was introduced as a notable player.

 

Therapex is poised to commence clinical trials for the development of EGFR-targeted anti-cancer agents with TRX-221.

 

This pipeline aims to treat a broad spectrum of mutations, from those targeted by first and second-generation EGFR-targeted anti-cancer agents such as Del19 and L858R, to the T790M mutation targeted by third-generation drugs. It even treats the C797S mutation, which emerges after treatments involving third-generation drugs.   

The development of a fourth-generation EGFR TKI by Therapex is aimed at creating a more effective first-in-class drug. This new drug aims to differentiate itself from existing first and third-generation EGFR-targeted drugs while addressing their limitations.

We expect positive outcomes in the clinical trial phases following preclinical research, with the goal of making a meaningful contribution to the global healthcare industry with this first-in-class drug.

 

 

Source : The Bell, Reporter Hong Sook (http://www.thebell.co.kr/free/content/ArticleView.asp?key=202307181722275720106356)


 

List